Reference:ICH ICH E6 Guideline R3 (2025) Appendix B - Revision history

Gxplex admin: 1 revision imported

2026-07-16T11:49:35Z

1 revision imported

← Older revision	Revision as of 13:49, 16 July 2026
(No difference)

GxPlexBot: Migrate to Template:ReferenceData for PageForms (GxPlexBot)

2026-07-16T10:55:20Z

Migrate to Template:ReferenceData for PageForms (GxPlexBot)

← Older revision		Revision as of 12:55, 16 July 2026
Line 1:		Line 1:
	{{~~#set:~~		{{ReferenceData
	\|~~HasDocument~~=Document:ICH ICH E6 Guideline R3 (2025)		\|has_document=Document:ICH ICH E6 Guideline R3 (2025)
	\|~~RefScope~~=G		\|module=2
	\|~~RefDocPart~~=Appendix B		\|unit=2.1.3
	\|~~RefLanguage~~=EN		\|scope=G
	\|~~RefTags~~=TAG-00033-Pro-oto ++ TAG-00041-Ame-run ++ TAG-00329-Saf-lne ++ TAG-00176-Ris-erh		\|doc_part=Appendix B
	\|~~RefModule=2~~		\|language=EN
	~~\|RefUnit~~=~~2.1.3~~		\|entry_by=Florian Adragna
	}}		\|contributors=
			\|tags=TAG-00033-Pro-oto ++ TAG-00041-Ame-run ++ TAG-00329-Saf-lne ++ TAG-00176-Ris-erh
	~~{{:Document:ICH ICH E6 Guideline R3 (2025)}}~~		\|tags_display=[[Glossary:TAG-00033-Pro-oto\|Protocol]], [[Glossary:TAG-00041-Ame-run\|Amendment]], [[Glossary:TAG-00329-Saf-lne\|Safety]], [[Glossary:TAG-00176-Ris-erh\|Risk]]
			\|comment=Clinical trial protocol and protocol amendment content
	~~{\| class="wikitable gplx-infobox"~~		\|content=Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
	\|-
	~~! colspan="2" class="gplx-infobox-header" \| Reference Details~~
	\|-
	~~! Module~~
	~~\| Module 2 — Unit 2.1.3~~
	\|-
	~~! Scope~~
	~~\| G~~
	\|-
	~~! Document part~~
	~~\| Appendix B~~
	\|-
	~~! Language~~
	~~\| EN~~
	\|-
	~~! Original entry by~~
	~~\| Florian Adragna~~
	\|-
	~~! Contributors~~
	\|
	\|-
	~~! Tags~~
	\| [[Glossary:TAG-00033-Pro-oto\|Protocol]], [[Glossary:TAG-00041-Ame-run\|Amendment]], [[Glossary:TAG-00329-Saf-lne\|Safety]], [[Glossary:TAG-00176-Ris-erh\|Risk]]
	\|-
	~~! Comment~~
	\| Clinical trial protocol and protocol amendment content
	\|}

	=~~= Content ==~~
	Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
	Clinical trials should be described in a clear, concise and operationally feasible protocol. The protocol should be designed in such a way as to minimise unnecessary complexity and to mitigate or eliminate important risks to the rights, safety, and well-being of trial participants and the reliability of data. Protocol development processes should incorporate input from relevant interested parties, where appropriate. Building adaptability into the protocol, for example, by including acceptable ranges for specific protocol provisions, can reduce the number of deviations or in some instances the requirement for a protocol amendment. Such adaptability should not adversely affect participant safety or the scientific validity of the trial. For additional information, refer to ICH E8(R1) General Considerations for Clinical Studies, ICH E9 Statistical Principles for Clinical Trials and ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.		Clinical trials should be described in a clear, concise and operationally feasible protocol. The protocol should be designed in such a way as to minimise unnecessary complexity and to mitigate or eliminate important risks to the rights, safety, and well-being of trial participants and the reliability of data. Protocol development processes should incorporate input from relevant interested parties, where appropriate. Building adaptability into the protocol, for example, by including acceptable ranges for specific protocol provisions, can reduce the number of deviations or in some instances the requirement for a protocol amendment. Such adaptability should not adversely affect participant safety or the scientific validity of the trial. For additional information, refer to ICH E8(R1) General Considerations for Clinical Studies, ICH E9 Statistical Principles for Clinical Trials and ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.
	The contents of a trial protocol should generally include the following topics, which may vary depending on the trial design. Investigator site-specific information may be provided on separate protocol page(s) or addressed in a separate agreement, and some of the information listed below may be contained in other protocol referenced documents, such as an Investigator’s Brochure.		The contents of a trial protocol should generally include the following topics, which may vary depending on the trial design. Investigator site-specific information may be provided on separate protocol page(s) or addressed in a separate agreement, and some of the information listed below may be contained in other protocol referenced documents, such as an Investigator’s Brochure.
			}}

gxplex>GxPlexBot: Import from GxPlex Excel

2026-07-15T15:29:01Z

Import from GxPlex Excel

← Older revision	Revision as of 17:29, 15 July 2026
(No difference)

imported>GxPlexBot: Import from GxPlex Excel

2026-07-15T15:29:01Z

Import from GxPlex Excel

← Older revision		Revision as of 17:29, 15 July 2026
Line 4:		Line 4:
	\|RefDocPart=Appendix B		\|RefDocPart=Appendix B
	\|RefLanguage=EN		\|RefLanguage=EN
	\|~~RefTagsEN~~=		\|RefTags=TAG-00033-Pro-oto ++ TAG-00041-Ame-run ++ TAG-00329-Saf-lne ++ TAG-00176-Ris-erh
	\|~~RefTagsOriginal~~=		\|RefModule=2
	\|~~RefTagsFR~~=		\|RefUnit=2.1.3
	}}		}}

Line 14:		Line 14:
	\|-		\|-
	! colspan="2" class="gplx-infobox-header" \| Reference Details		! colspan="2" class="gplx-infobox-header" \| Reference Details
			\|-
			! Module
			\| Module 2 — Unit 2.1.3
	\|-		\|-
	! Scope		! Scope
Line 30:		Line 33:
	\|		\|
	\|-		\|-
	! Tags ~~(EN)~~		! Tags
	\|		\| [[Glossary:TAG-00033-Pro-oto\|Protocol]], [[Glossary:TAG-00041-Ame-run\|Amendment]], [[Glossary:TAG-00329-Saf-lne\|Safety]], [[Glossary:TAG-00176-Ris-erh\|Risk]]
	\|-
	~~! Tags (original language)~~
	\|
	\|-
	~~! Tags (FR)~~
	\|
	\|-		\|-
	! Comment		! Comment

Gxplex admin: 1 revision imported

2026-06-29T13:28:41Z

1 revision imported

← Older revision	Revision as of 15:28, 29 June 2026
(No difference)

gxplex>GxPlexBot: Import from GxPlex Excel

2026-06-29T13:27:17Z

Import from GxPlex Excel

← Older revision		Revision as of 15:27, 29 June 2026
Line 11:		Line 11:
	{{:Document:ICH ICH E6 Guideline R3 (2025)}}		{{:Document:ICH ICH E6 Guideline R3 (2025)}}

	{\| class="gplx-infobox"		{\| class="wikitable gplx-infobox"
	\|-		\|-
	! colspan="2" class="gplx-infobox-header" \| Reference Details		! colspan="2" class="gplx-infobox-header" \| Reference Details

Gxplex admin: 1 revision imported

2026-06-29T13:07:47Z

1 revision imported

← Older revision	Revision as of 15:07, 29 June 2026
(No difference)

gxplex>GxPlexBot: Import from GxPlex Excel

2026-06-29T13:06:54Z

Import from GxPlex Excel

← Older revision	Revision as of 15:06, 29 June 2026
(No difference)

Gxplex admin: 1 revision imported

2026-06-29T12:51:47Z

1 revision imported

← Older revision	Revision as of 14:51, 29 June 2026
(No difference)

gxplex>GxPlexBot: Import from GxPlex Excel

2026-06-29T12:27:21Z

Import from GxPlex Excel

← Older revision		Revision as of 14:27, 29 June 2026
Line 9:		Line 9:
	}}		}}

	~~== Document Information ==~~
	{{:Document:ICH ICH E6 Guideline R3 (2025)}}		{{:Document:ICH ICH E6 Guideline R3 (2025)}}

	~~== Reference Details ==~~		{\| class="gplx-infobox"
	{\| class="~~wikitable" style="width:100%;~~"
	\|-		\|-
	! ~~scope~~="~~row~~" ~~style~~="~~width:200px;~~" \| Scope		! colspan="2" class="gplx-infobox-header" \| Reference Details
			\|-
			! Scope
	\| G		\| G
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Document part		! Document part
	\| Appendix B		\| Appendix B
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Language		! Language
	\| EN		\| EN
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Original entry by		! Original entry by
	\| Florian Adragna		\| Florian Adragna
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Contributors		! Contributors
	\|		\|
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Tags (EN)		! Tags (EN)
	\|		\|
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Tags (original language)		! Tags (original language)
	\|		\|
	\|-		\|-
	! ~~scope="row" style="width:200px;" \|~~ Tags (FR)		! Tags (FR)
	\|		\|
	\|-		\|-
	! ~~scope="row" \|~~ Comment		! Comment
	\| Clinical trial protocol and protocol amendment content		\| Clinical trial protocol and protocol amendment content
	\|}		\|}

	== ~~Text~~ ==		== Content ==
	Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)		Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
	Clinical trials should be described in a clear, concise and operationally feasible protocol. The protocol should be designed in such a way as to minimise unnecessary complexity and to mitigate or eliminate important risks to the rights, safety, and well-being of trial participants and the reliability of data. Protocol development processes should incorporate input from relevant interested parties, where appropriate. Building adaptability into the protocol, for example, by including acceptable ranges for specific protocol provisions, can reduce the number of deviations or in some instances the requirement for a protocol amendment. Such adaptability should not adversely affect participant safety or the scientific validity of the trial. For additional information, refer to ICH E8(R1) General Considerations for Clinical Studies, ICH E9 Statistical Principles for Clinical Trials and ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.		Clinical trials should be described in a clear, concise and operationally feasible protocol. The protocol should be designed in such a way as to minimise unnecessary complexity and to mitigate or eliminate important risks to the rights, safety, and well-being of trial participants and the reliability of data. Protocol development processes should incorporate input from relevant interested parties, where appropriate. Building adaptability into the protocol, for example, by including acceptable ranges for specific protocol provisions, can reduce the number of deviations or in some instances the requirement for a protocol amendment. Such adaptability should not adversely affect participant safety or the scientific validity of the trial. For additional information, refer to ICH E8(R1) General Considerations for Clinical Studies, ICH E9 Statistical Principles for Clinical Trials and ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.
	The contents of a trial protocol should generally include the following topics, which may vary depending on the trial design. Investigator site-specific information may be provided on separate protocol page(s) or addressed in a separate agreement, and some of the information listed below may be contained in other protocol referenced documents, such as an Investigator’s Brochure.		The contents of a trial protocol should generally include the following topics, which may vary depending on the trial design. Investigator site-specific information may be provided on separate protocol page(s) or addressed in a separate agreement, and some of the information listed below may be contained in other protocol referenced documents, such as an Investigator’s Brochure.